Last reviewed · How we verify
MEDI4736
MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.
MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses. Used for Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy, Metastatic or unresectable locally advanced urothelial carcinoma, Metastatic gastric or gastroesophageal junction adenocarcinoma.
At a glance
| Generic name | MEDI4736 |
|---|---|
| Also known as | Durvalumab, tremelimumab, anti-PD-L1 antibody, durvalumab |
| Sponsor | MedImmune LLC |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MEDI4736 (durvalumab) binds to programmed death ligand-1 (PD-L1) on tumor cells and immune cells, blocking the inhibitory PD-L1/PD-1 axis that tumors exploit to evade immune surveillance. By preventing this interaction, the drug restores T-cell activation and proliferation, enabling the immune system to recognize and attack cancer cells. This mechanism is particularly effective in tumors with high PD-L1 expression.
Approved indications
- Unresectable stage III non-small cell lung cancer (NSCLC) after concurrent chemoradiotherapy
- Metastatic or unresectable locally advanced urothelial carcinoma
- Metastatic gastric or gastroesophageal junction adenocarcinoma
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-mediated pneumonitis
- Immune-mediated hepatitis
- Immune-mediated colitis
- Diarrhea
Key clinical trials
- Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial (PHASE2)
- Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial (PHASE3)
- Durvalumab as Consolidation for Patients LS-SCLC (PHASE2)
- Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery (PHASE2)
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer (PHASE2)
- Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer (PHASE2)
- MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract Carcinoma (PHASE2)
- Thoracic Radiotherapy Plus Durvalumab in Elderly and/or Frail NSCLC Stage III Patients Unfit for Chemotherapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MEDI4736 CI brief — competitive landscape report
- MEDI4736 updates RSS · CI watch RSS
- MedImmune LLC portfolio CI